CNI-1493 mediated suppression of dendritic cell activation in vitro and in vivo

Immunobiology

Volumn 209, Issue 1-2, 2004, Pages 89-97

  Zinser, Elisabeth ^a   Turza, Nadine ^a   Steinkasserer, Alexander ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Dendritic cells; Experimental allergic encephalomyelitis

Indexed keywords

CD83 ANTIGEN; CYTOKINE; SEMAPIMOD;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLOGY; DENDRITIC CELL; DISEASE MODEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INHIBITION KINETICS; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; SYMPTOM; T LYMPHOCYTE ACTIVATION;

EID: 4544377322     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2004.04.004     Document Type: Article

References (20)

1. Atkins, M.R., Redman, B., Mier, J., Gollob, J., Weber, J., Sosman, J., MacPherson, B.L., Plasse, T., 2001. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin. Cancer Res. 7, 486-492.
2. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebeque, S., Liu, Y-J., Pulendran, B., Palucka, K., 2000. Immunology of dendritic cells. Annu. Rev. Immunol. 18, 767-811.
3. Bernik, T.R., Friedman, S.G., Ochani, M., DiRaimo, R., Ulloa, L., Yang, H., Sudan, S., Czura, C.J., Ivanova, S.M., Tracey, K.J., 2002. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J. Exp. Med. 195, 781-788.
4. Bianchi, M., Ulrich, P., Bloom, O., Meistrell, M., Zimmermann, G.A., Schmidtmayerova, H., Bukrinsky, M., Donnelley, T., Bucala, R., Sherry, B., Manogue, K.R., Tortolani, A.J., Cerami, A., Tracey, K.J., 1995. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol. Med. 1, 254-266.
5. Bianchi, M., Bloom, O., Raabe, T., Cohen, P.S., Chesney, J., Sherry, B., Schmidtmayerova, H., Calandra, T., Zhang, X., Burinsky, M., Ulrich, P., Cerami, A., Tracey, K.J., 1996. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J. Exp. Med. 183, 927-936.
6. Cohen, P.S., Nakshatri, H., Dennis, J., Caragine, T., Bianchi, M., Cerami, A., Tracey, K.J., 1996. CNI_1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc. Natl. Acad. Sci. USA 93, 3967-3971.
7. Cohen, P.S., Schmidtmayerova, H., Dennis, J., Dubrovsky, L., Sherry, B., Wang, H., Burinsky, M., Tracey, K.J., 1997. The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol. Med. 3, 339-346.
8. Hibbs, J.B., Westenfelder, C., Taintor, R., Vavrin, Z., Kablitz, C., Baranowsky, R.L., Ward, J.H., Menlove, R.L., McMurry, M.P., Kushner, J.P., et al., 1992. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest. 89, 867-877.
9. Kemeny, M.M., Botchkina, G.I., Ochani, M., Bianchi, M., Urmacher, C., Tracey, K.J., 1998. The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor activity. Proc. Natl. Acad. Sci. USA 95, 4561-4566.
10. Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Kaempgen, E., Romani, N., Schuler, G., 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 downmodulation by IL-4 and I1-10. J. Exp. Med. 184, 741-746.
11. Kruse, M., Rosorius, O., Kratzer, F., Bevec, D., Kuhnt, C., Steinkasserer, A., Schuler, G., Hauber, J., 2000. Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J. Exp. Med. 191, 1581-1590.
12. Lutz, M.B., Schuler, G., 2002. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23, 445-449.
13. Martiney, J.A., Rajan, A.J., Charles, P.C., Cerami, A., Ulrich, P.C., Macphail, S., Tracey, K.J., Brosnan, C.F., 1998. Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent. J. Immunol. 160, 5588-5595.
14. Ochoa, J.B., Curti, B., Peitzmann, A.B., Simmons, R.L., Biliar, T.R., Hoffmann, R., Longo, D.L., Urba, W.J., Ochoa, A.C., 1992. Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J. Natl. Cancer Inst. 84, 864-867.
15. Sallusto, F., Lanzavecchia, A., 1999. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J. Exp. Med. 189, 611-614.
16. Steinman, L., 2003. Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year. J. Exp. Med. 197, 1065-1071.
17. Steinman, R.M., 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296.
18. Tracey, K.J., 1998. Suppression of TNF and other proinflammatory cytokines by the tetravalent guanylhydrazone CNI-1493. Prog. Clin. Biol. Res. 397, 335-343.
19. Wong, B.R., Josien, R., Lee, S.Y., Sauter, B., Li, H., Steinman, R.M., Choi, Y., 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 188, 2075-2080.
20. Zhou, L.J., Tedder, T.F., 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154, 3821-3835.